Skip to main content

Table 2 Seroconversion and post-vaccination antibody levels when YF and MMR are co-administered or administered individually

From: Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina

 

MMR & YF vaccines co-administered*

MMR or YF vaccine administered individually as first vaccine in a series*

Difference in seroconversion or

p-value for comparison of antibody titers/ concentrations†

Interpretation

Measles

MMR 1 YF 1

MMR 1 YF 2

  

Intention-to-treat analysis

(n = 242)

(n = 245)

  

Seroconversion

97.9 (95.3–99.1)

96.3 (93.2–98.1)

1.6 (-1.5–4.7)

Co-administration is non-inferior to individual administration

Antibody concentrations, mIU

2024 (1705–2402)

1638 (1323–2028)

0.175

No significant difference

Per protocol analysis

(n = 203)

(n = 220)

  

Seroconversion

98.0 (95.0–99.2)

96.4 (93.0–98.2)

1.7 (-1.7–5.0)

Co-administration is non-inferior to individual administration

Antibody concentrations, mIU

1956 (1629–2348)

1569 (1253–1964)

0.188

No significant difference

Rubella

MMR 1 YF 1

MMR 1 YF 2

  

Intention-to-treat analysis

(n = 241)

(n = 243)

  

Seroconversion

97.9 (95.2–99.1)

94.7 (91.0–96.9)

3.3 (-0.1–6.7)

Co-administration is non-inferior to individual administration

Antibody concentrations, IU

35.8 (31.5–40.7)

40.8 (35.0–47.5)

0.006

Individual administration has higher concentrations

Per protocol analysis

(n = 202)

(n = 218)

  

Seroconversion

97.5 (94.3–98.9)

94.5 (90.6–96.8)

3.0 (-0.7–6.8)

Co-administration is non-inferior to individual administration

Antibody concentrations, IU

32.2 (28.0–37.1)

39.4 (33.5–46.3)

0.001

Individual administration has higher concentrations

Mumps

MMR 1 YF 1

MMR 1 YF 2

  

Intent-to-treat analysis

(n = 242)

(n = 243)

  

Seroconversion

96.7 (93.6–98.3)

97.9 (95.3–99.1)

-1.3 (-4.1–1.6)

Co-administration is non-inferior to individual administration

Antibody concentrations, U

1807 (1470–2220)

2252 (1877–2701)

0.082

No significant difference

Per protocol analysis

(n = 203)

(n = 218)

  

Seroconversion

96.6 (93.1–98.3)

98.2 (95.4–99.3)

-1.6 (-4.7–1.5)

Co-administration is non-inferior to individual administration

Antibody concentrations, U

1746 (1390–2192)

2319 (1926–2792)

0.037

Individual administration has higher concentrations

Yellow Fever

MMR 1 YF 1

YF 1 MMR 2

  

Intention-to-treat analysis

(n = 244)

(n = 243)

  

Seroconversion

96.3 (93.1–98.1)

97.5 (94.7–98.9)

-1.2 (-4.2–1.7)

Co-administration is non-inferior to individual administration

Antibody titers

219 (181–265)

340 (283–408)

< 0.0001

Individual administration has higher titers

Per protocol analysis

(n = 205)

(n = 206)

  

Seroconversion

96.1 (92.5–98.0)

98.1 (95.1–99.2)

-2.0 (-5.1–1.2)

Non-inferiority of co-administration not shown

Antibody titers

225 (181–279)

373 (308–452)

< 0.0001

Individual administration has higher titers

  1. *Data shown for seroconversion are percentages and 95% CI. Data shown for antibody concentrations are geometric mean concentrations and 95% CI. Data shown for antibody titers are geometric mean titer and 95% CI.
  2. †Data shown are the difference in seroconversion and Farrington-Manning 90% CI or the p-value for Wilcoxon Rank Sum test comparing antibody titers/concentrations.